741 related articles for article (PubMed ID: 28368337)
1. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.
Monteys AM; Ebanks SA; Keiser MS; Davidson BL
Mol Ther; 2017 Jan; 25(1):12-23. PubMed ID: 28129107
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
Yang S; Chang R; Yang H; Zhao T; Hong Y; Kong HE; Sun X; Qin Z; Jin P; Li S; Li XJ
J Clin Invest; 2017 Jun; 127(7):2719-2724. PubMed ID: 28628038
[TBL] [Abstract][Full Text] [Related]
4. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
[TBL] [Abstract][Full Text] [Related]
5. Allele-specific silencing of the gain-of-function mutation in Huntington's disease using CRISPR/Cas9.
Shin JW; Hong EP; Park SS; Choi DE; Seong IS; Whittaker MN; Kleinstiver BP; Chen RZ; Lee JM
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040815
[TBL] [Abstract][Full Text] [Related]
6. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.
Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692
[TBL] [Abstract][Full Text] [Related]
7. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
Shin JW; Kim KH; Chao MJ; Atwal RS; Gillis T; MacDonald ME; Gusella JF; Lee JM
Hum Mol Genet; 2016 Oct; 25(20):4566-4576. PubMed ID: 28172889
[TBL] [Abstract][Full Text] [Related]
8. Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease.
Molero AE; Arteaga-Bracho EE; Chen CH; Gulinello M; Winchester ML; Pichamoorthy N; Gokhan S; Khodakhah K; Mehler MF
Proc Natl Acad Sci U S A; 2016 May; 113(20):5736-41. PubMed ID: 27140644
[TBL] [Abstract][Full Text] [Related]
9. Limitations of Dual-Single Guide RNA CRISPR Strategies for the Treatment of Central Nervous System Genetic Disorders.
Duarte F; Vachey G; Caron NS; Sipion M; Rey M; Perrier AL; Hayden MR; Déglon N
Hum Gene Ther; 2023 Sep; 34(17-18):958-974. PubMed ID: 37658843
[TBL] [Abstract][Full Text] [Related]
10. Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities.
Oikemus SR; Pfister EL; Sapp E; Chase KO; Kennington LA; Hudgens E; Miller R; Zhu LJ; Chaudhary A; Mick EO; Sena-Esteves M; Wolfe SA; DiFiglia M; Aronin N; Brodsky MH
Hum Gene Ther; 2022 Jan; 33(1-2):25-36. PubMed ID: 34376056
[TBL] [Abstract][Full Text] [Related]
11. Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.
Tabrizi SJ; Ghosh R; Leavitt BR
Neuron; 2019 Mar; 101(5):801-819. PubMed ID: 30844400
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease.
Alkanli SS; Alkanli N; Ay A; Albeniz I
Mol Neurobiol; 2023 Mar; 60(3):1486-1498. PubMed ID: 36482283
[TBL] [Abstract][Full Text] [Related]
13. HuR stabilizes
Zhao Q; Li C; Yu M; Sun Y; Wang J; Ma L; Sun X; Lu B
RNA Biol; 2020 Apr; 17(4):500-516. PubMed ID: 31928144
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
Elife; 2021 Apr; 10():. PubMed ID: 33871358
[TBL] [Abstract][Full Text] [Related]
15. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice.
Petkau TL; Hill A; Connolly C; Lu G; Wagner P; Kosior N; Blanco J; Leavitt BR
Hum Mol Genet; 2019 May; 28(10):1661-1670. PubMed ID: 30624705
[TBL] [Abstract][Full Text] [Related]
16. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
[TBL] [Abstract][Full Text] [Related]
17. Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon?
Liu W; Pfister EL; Kennington LA; Chase KO; Mueller C; DiFiglia M; Aronin N
J Huntingtons Dis; 2016; 5(1):33-8. PubMed ID: 27003665
[TBL] [Abstract][Full Text] [Related]
18. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.
Pfister EL; DiNardo N; Mondo E; Borel F; Conroy F; Fraser C; Gernoux G; Han X; Hu D; Johnson E; Kennington L; Liu P; Reid SJ; Sapp E; Vodicka P; Kuchel T; Morton AJ; Howland D; Moser R; Sena-Esteves M; Gao G; Mueller C; DiFiglia M; Aronin N
Hum Gene Ther; 2018 Jun; 29(6):663-673. PubMed ID: 29207890
[TBL] [Abstract][Full Text] [Related]
19. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
[TBL] [Abstract][Full Text] [Related]
20. Lycium barbarum polysaccharide attenuates the cytotoxicity of mutant huntingtin and increases the activity of AKT.
Fang F; Peng T; Yang S; Wang W; Zhang Y; Li H
Int J Dev Neurosci; 2016 Aug; 52():66-74. PubMed ID: 27196502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
